Search results for " monoclonal" in Articles / App Notes
Article
The Evolving Role of Starting Materials in Cell and Gene Therapy
Unlike other biological drug products such as therapeutic proteins, monoclonal antibodies, or vaccines, drugs based on living cells are by nature uniquely vulnerable to supply chain complications and …
Article
A Continuous Confidence Boost
Continuous processing of monoclonal antibodies (mAb) could offer a number of advantages, but regulatory uncertainty and upfront investment remain sticking points.
In this case study, Shanghai Henli…
Article
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU
England (Taylor Wessing): Increasing patent litigation is being seen concerning biosimilar versions of biological products, most often monoclonal antibody treatments. The complexity and value of these…
Article
New Therapies Present Scaling Challenges
However, differences in manufacturing cycles for emerging therapies, compared with that of the traditional monoclonal antibody (mAb) therapeutic, calls for different strategies to increase production.…
Article
Driving Improved Access to Biosimilars
Thomas Linneman, head of regulation CMC customer solutions at Solvias, divides them into monoclonal antibodies, hormones, and Fc fusion proteins and cytokines (4). Although approved, these drugs are n…
Article
2019 HTPD Conference Abstract Submissions Are Coming Up: What Happened Last Time?
HTPD 2019 will cover process development spanning upstream through downstream processing for both monoclonal antibodies (mAbs), Ab-like molecules as well as novel biomolecules. Sessions will …
Article
Intensified Chromatography Strategies
The blockbuster drug era is over and drug manufacturers are now striving for a more diversified portfolio by targeting a greater number of monoclonal antibody (mAb) products at lower production volu…
Article
Design Considerations for a Commercial Cell and Gene Therapy Facility
Different from mAbs
Considering the differences between monoclonal antibody (mAb) production and cell/gene therapy production is also important when establishing a cell/gene therapy facility. Al…
Article
Moving PAT from Concept to Reality
These products are not well-characterized molecules like monoclonal antibodies, but a complex of various proteins, DNA/RNA, and in some cases lipid membranes. “This complexity makes it hard to identif…
Article
Getting a Handle on Biopharma’s Most Critical Quality Attributes and Quality Control
While the multiple attributes method gains ground and traditional lab methods improve, broad efforts are underway to determine biopharmaceuticals’ most significant critical quality attributes and en…